Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

Read the full news release HERE

Capricor Therapeutics, which received early funding from CureDuchenne, has announced positive 3-year results from the HOPE-2 open-label extension study.  Individuals receiving CAP-1002 continue to show upper-limb and cardiac benefits after 3 years of treatment, compared to an external control group of similar DMD patients.  Results from the pivotal Phase 3 HOPE-3 trial are expected in the fourth quarter of 2024.